CJC-1295 + Ipamorelin: The Growth Hormone Axis Explained

CJC-1295 and ipamorelin are two synthetic peptides that stimulate the pituitary gland to release more of the body's own growth hormone, and they are frequently promoted together as an anti-aging "stack." The biology behind combining them is real, but human evidence is limited to small, short pharmacology studies, neither compound is FDA-approved, and as of this writing neither can be legally compounded by U.S. pharmacies. Understanding the growth hormone axis explains both their appeal and their limits.

The Growth Hormone Axis in Plain English

Growth hormone (GH) is released by the pituitary gland in pulses, mostly during deep sleep. Two signals from the brain control those pulses:

• Growth hormone-releasing hormone (GHRH) from the hypothalamus tells the pituitary to release GH.
• Somatostatin tells it to stop.

A third signal, ghrelin — a hormone made largely in the stomach — acts on its own receptor (the growth hormone secretagogue receptor) and amplifies GH release.

GH then travels to the liver and other tissues, which produce insulin-like growth factor 1 (IGF-1). IGF-1 carries out many of GH's effects on muscle, bone and metabolism, and it also feeds back to the brain to slow further GH release. That feedback loop is one of the body's built-in safety brakes. I explain IGF-1 in more depth in Understanding IGF-1.

GH secretion declines gradually with age, and lower GH and IGF-1 are associated with loss of muscle mass and more abdominal fat. Whether boosting GH in healthy older adults improves long-term health, rather than just changing lab numbers and body composition, has not been established.

How CJC-1295 and Ipamorelin Work

CJC-1295: a modified GHRH signal

CJC-1295 is a synthetic analog of the first 29 amino acids of GHRH, altered so enzymes break it down less quickly. It comes in two forms:

• Without DAC (often called "Mod GRF 1-29"): a short half-life of roughly half an hour, producing a brief pulse of GH.
• With DAC (Drug Affinity Complex): a chemical attachment that binds the peptide to albumin in the blood, extending its activity to roughly a week and producing a more sustained rise in GH.

In a 2006 study in healthy adults, single injections of the DAC version produced dose-dependent increases in GH and IGF-1 that lasted for days. That study is useful pharmacology, but it measured hormone levels — not muscle, fat, function, or long-term safety.

Ipamorelin: a selective ghrelin-receptor signal

Ipamorelin is a five-amino-acid peptide that activates the ghrelin receptor. Its original 1998 characterization in animals described it as a selective GH secretagogue: unlike older compounds in its class, it did not meaningfully raise cortisol or prolactin at the doses studied. Human efficacy data are sparse. A clinical program testing ipamorelin for postoperative bowel recovery did not show a clear benefit, and it has never been approved for any condition.

Why they are paired

Because GHRH and ghrelin act through different receptors, stimulating both at once produces a larger GH pulse than either alone. This synergy is well described in endocrine physiology. What is missing are controlled human trials testing the specific CJC-1295 and ipamorelin combination for meaningful outcomes.

What the Evidence Does and Does Not Show

Reasonably established: Both compounds raise GH and IGF-1 levels in the short term. The mechanism of each is well understood.

Promising but unproven: Claims about improved body composition, sleep quality, recovery, skin and energy come largely from extrapolation from growth hormone research, animal studies and personal reports.

Unknown: Long-term safety of repeatedly stimulating the GH axis in healthy adults, effects on cancer risk, and whether any benefit translates into longer or healthier life.

The IGF-1 and cancer question

Higher IGF-1 levels have been associated with higher risk of some cancers in observational studies. That association does not prove that GH-axis peptides cause cancer, but it is a reasonable concern, and it is why these compounds are avoided in anyone with active or recent cancer. Other known effects of excess GH signaling include fluid retention, joint aches, carpal tunnel symptoms and reduced insulin sensitivity, which can raise blood sugar.

Regulatory Status: Where Things Stand

This area has changed quickly, so precision matters:

• Not FDA-approved. Neither CJC-1295 nor ipamorelin is approved for any medical use in the United States.
• Compounding restricted. In 2023, FDA placed both on its "Category 2" list of bulk substances that may present significant safety risks. FDA cited concerns about immunogenicity and peptide impurities, and it described serious adverse events reported with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
• Advisory votes against. FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin (October 2024) and CJC-1295 (December 2024) to the list of substances pharmacies may compound. Neither was among the 12 peptides FDA removed from Category 2 in April 2026.
• Banned in sport. Both are prohibited by the World Anti-Doping Agency.

Regulations continue to evolve, so check current FDA guidance before relying on any status statement, including this one.

Approved Options on the Same Axis

Tesamorelin is an FDA-approved GHRH analog, approved specifically to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Sermorelin, another GHRH analog, was once FDA-approved but was discontinued by its manufacturer in 2008 for commercial reasons. For adults with true growth hormone deficiency — diagnosed with formal stimulation testing — prescription growth hormone is the established treatment, managed by an endocrinologist. You can read more in Tesamorelin: The FDA-Approved Peptide for Visceral Fat Reduction.

How I Approach Growth Hormone Questions

At Laeeq M.D., a question about growth hormone peptides starts with internal medicine: sleep quality and sleep apnea screening, training and nutrition, body composition, glucose control, thyroid and sex hormone status, and IGF-1 in context. Many of the symptoms people attribute to "low growth hormone" have more common, more treatable causes. When the GH axis is a reasonable focus, we discuss only options that are legal and supported by evidence, and any treatment decisions are individualized after evaluation and labs.

Sources

• Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults — Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism, 2006
• Ipamorelin, the first selective growth hormone secretagogue — Raun K, et al. European Journal of Endocrinology, 1998
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration, updated 2026

Book a Consultation

If you are wondering whether your energy, recovery or body composition concerns involve the growth hormone axis, start with a careful evaluation rather than a product. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA. Book a consultation to review your history, labs and goals.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.